First guidance in this area from the Agency addresses the unique challenges when designing clinical studies for these drugsThe FDA published its first draft guidance that presents considerations to industry for designing clinical trials for psychedelic drugs.1 In the guidance, the FDA says the term psychedelic includes classic psychedelics, typically understood to be 5-HT2 agonists […]
